Medicines in development in 2009 for colorectal cancers
SciMedWeb
● 1018 ISS Phase I
● A-007 Phase I/II
● ABT-751 Phase II
● aflibercept (VEGF-trap) Phase III
● AMG 102 Phase I/II
● AMG 479 Phase II
● AMG 951 (rhApo2L/TRAIL) Phase I
● apomab Phase I
● AR-726 Phase II
● Avastin (bevacizumab) Phase III
● AVX701 Phase I/II
● axitinib Phase II
● belinostat Phase I
● brivanib (VEGFR/FGFR kinase inhibitor) Phase III
● CDX-1307 Phase I
● conatumumab Phase II
● CP-751871 Phase II
● CPX-1 Phase II
● Davanat (galactomannan C) Phase II
● denenicokin (IL-21) Phase I
● edotecarin Phase III
● enzastaurin (LY317615) Phase II
● Erbitux (cetuximab) Phase III
● Fusilev (levoleucovorin)
● Herceptin (trastuzumab) Phase II
● huA33 Phase I
● Hycamtin (topotecan) Phase II
● IMC-1121B Phase II
● IMC-A12 Phase II
● IMO-2055 Phase I
● ispinesib Phase II
● KRN-330 Phase I
● KRX-0402 Phase I
● lapuleucel-T Phase I
● LE-SN38 Phase II
● Levulan (aminolevulinic acid)
● Litx (talaporfin) Phase III
● LOR-2040 Phase II
● milataxel Phase II
● motesanib Phase I
● NKTR-102 Phase II
● Oncophage (vitespen) Phase II
● OncoVAX (cancer vaccine) Phase II
● patupilone (EPO906) Phase I/II
● pelitinib (EKB569) Phase II
● picoplatin Phase II
● PN401 Phase I
● PV701 Phase II
● RIGScan® CR49 (radiodiagnostic agent) Phase III
● RM1812 Phase I
● robatumumab Phase II
● sibrotuzumab Phase II
● Sutent (sunitinib) Phase II
● systemic hedgehog antagonist Phase II
● Tarceva (erlotinib) Phase II
● TAS-109 Phase II
● tegafur/uracil combination Phase III
● Telcyta (canfosfamide) Phase II
● tesetaxel Phase II
● tetrandrine Phase III
● Thymitaq (nolatrexed) Phase II
● TNFerade Phase II
● Torisel (temsirolimus) Phase II
● tremelimumab Phase II
● tucotuzumab (celmoleukin) Phase II
● Urso Forte (ursodeoxycholic acid) Phase II
● VP101 Phase II
● Xeloda (capecitabine)
● Zolinza (vorinostat) Phase I
● ZYC300 Phase I
InTextoResearch, Baelen, Liège, Wallonie (Wallonia), Belgique
(Belgium) & Agence Wallonne d’Information Scientifique (AWIS) (Marc
Lacroix, scim...@mail.com)